Tuesday, 19 Nov 2019

You are here

The Risk of Tuberculosis with TNF Inhibitors

A study from Turkey shows that among 2117 patients treated with a TNF inhibitor (TNFi) the risk of developing TB was 6 fold higher in those treated with a TNFi compared to non-users.

This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without TNFI. The calculated the 2-year RR of TB after TNFi.

Among 413 500 rheumatic patients, 2117 received TNFi. Four patients among anti-TNF-α users developed TB compared to 128 patients in anti-TNF-α-naïve group (189 vs 31 cases per 100 000 patients, respectively). The 2-year risk of TB (RR) was  6.07 (95% CI, 2.25-16.42).

The risk was higher in men (RR 5.39; 1.69-7.17), adults (6.12; 2.26-16.55) and RA (5.70; 1.41-23.08) and PsA (13.46; 1.58-114.40).

These findings are similar to other studies showing a higher risk of TB with TNFi users. 

Another report from Romania assessed the incidence of active TB and the efficacy of TB prevention measures. (Citation source:https://buff.ly/2vYGpHj

Patients were divided into 3 groups according to LTBI screening: tuberculin skin test (TST) with a positive threshold of either 10 mm (group TST1), or 5 mm (group TST2), and QuantiFERON®-TB Gold test (group QFT).

Among 550 patients included (305 RA, 42 PsA, 203 AS). The number of TB cases/time of exposure to TNFi (person-years, PY) was 8/593.5, 9/1044.0 and 3/555.3, respectively, accounting for an incidence of 1348.0, 862.1 and 540.2 cases per 105 PY.

The number of active early TB cases (in the first year of TNFi) was relatively few - only 3/8, 1/9 and 1/3.

Overall there were less TB cases in the QFT group, probably due to the reduced duration of exposure to TNFi.

In this cohort study, TB was more likely to occur after 1 year of TNFi treatment, rather than early, suggesting the need for ongoing monitoring and TB prevention measures, especially in high risk areas and populations.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Pain Persists Despite TNF Inhibitor Use

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.

Adalimumab and Pregnancy Outcomes

A prospective study of birth outcomes to mothers exposed to adalimumab (ADA) between 2004 and 2016 was conducted by Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego, and showed that ADA exposure was not associated with an increased risk for any of the adverse outcomes examined.

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).